Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2016, Vol. 38 ›› Issue (1): 88-92.doi: 10.3881/j.issn.1000-503X.2016.01.016

• Orginal Article • Previous Articles     Next Articles

Clinical Outcome of 131I Therapy in Differentiated Thyroid Cancer with Preablative Thyroglobulin below 10 ng/ml

Xin-feng LIU1, Jiao LI2, Teng ZHAO2, Min HOU1, Hui LI1, Jun LIANG2(), Yan-song LIN1()   

  1. 1Department of Nuclear Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
    2Department of Oncology,the Affiliated Hospital of Qingdao University,Qingdao,Shandong 266003,China
  • Received:2015-03-02 Online:2016-01-15 Published:2016-03-02
  • Supported by:
    Supported by the National Natural Sciences Foundation of China (30970850)and the Ministry of Health Industry Special Scientific Research Project (201202012)

Abstract:

Objective To investigate the clinical outcome of 131I therapy in differentiated thyroid cancer(DTC) with preablative stimulated thyroglobulin(ps-Tg)below 10 ng/ml and the value of ps-Tg for predicting clinical outcome. Methods Totally 167 DTC patients with ps-Tg below 10 ng/ml were included and divided into three groups [excellent response (ER,n=131),acceptable response (AR,n=34),and incomplete response (IR,n=2)] according to the response to initial 131I therapy. One-way analysis of variance,χ2 test,and Kruskal-Wallis test were used to evaluate the statistical differences of clinicopathological features,recurrence risk,and ps-Tg value among the three groups. The ps-Tg value between ER group and non-ER group were compared by Mann-Whitney rank-sum test. The ROC curve and optimal cut-off point were analyzed to evaluate the clinical value of ps-Tg for predicting disease-free status. Results There was significant difference in ps-Tg level (H=14.305,P=0.001) among three groups but not in age (F=0.831,P=0.755),sex(χ2=0.178,P=0.915),cervical lymph node metastases(χ2=1.475,P=0.478),TNM stage(H=1.063,P=0.588),and recurrence risk (H=2.947,P=0.229). The median level of ps-Tg in ER group was 2.20 ng/ml(1.10,4.40),which was significantly lower than 4.40 ng/ml (2.70,5.90)of non-ER groups (U=1424.50,P=0.000). Area under the ROC curve was 0.717. The cut-off value of ps-Tg was 2.35 ng/ml,with a sensitivity of 83.33%,specificity of 53.43%,and negative predictive value of 92.11%. Conclusion The serum ps-Tg value is a sensitive marker for predicting the disease-free status in DTC patients with ps-Tg below 10 ng/ml.

Key words: differentiated thyroid cancer, thyroglobulin, 131I therapy, clinical outcome

CLC Number: